TEV-48125

https://clinicaltrials.gov/ct2/show/NCT04355117?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14

Condition :   Migraine

Intervention :   Drug: Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.

Sponsor :   Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

NCT04355117

Tue, 21 Apr 2020 12:00:00 EDT

Last Update Posted: 04/21/20 06:59AM

https://clinicaltrials.gov/ct2/show/NCT03303105?type=Intr&cond=Migraine&lupd_s=02%2F27%2F2019&lupd_d=14

Condition :   Migraine

Intervention :   Drug: TEV-48125

Sponsor :   Otsuka Pharmaceutical Co., Ltd.

Recruiting

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

NCT03303105

Thu, 05 Oct 2017 12:00:00 EDT

Last Update Posted: 03/13/19 10:21AM